Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ARG1 | P05089 | 1/20 | 0.31 |
| ▸ | ARG2 | P78540 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1543252 | 0.78 | ARG1 (0.35) | CYP1A2ARG1ARG2CYP2C19 | |
| SCHEMBL13010603 | 0.77 | CYP2C19 (0.45) | TP53CYP2C19 | |
| SCHEMBL9469790 | 0.71 | CYP4F2 (0.37) | — | |
| SCHEMBL9469793 | 0.71 | CYP4F2 (0.37) | — | |
| SCHEMBL6979479 | 0.70 | CYP2C19 (0.33) | CYP1A2CYP2C19 | |
| SCHEMBL27542500 | 0.69 | CYP4F2 (0.42) | ARG1ARG2EPHX2 | |
| Hydrochloric Acid SCHEMBL385319 | 0.68 | GNAI3 (0.34) | CYP2C19 | |
| Hydrochloric Acid SCHEMBL385321 | 0.68 | GNAI3 (0.34) | CYP2C19 | |
| Hydrochloric Acid SCHEMBL27539970 | 0.68 | CYP4F2 (0.41) | EPHX2 | |
| SCHEMBL31145967 | 0.65 | CYP4F2 (0.47) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243187-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-07-31 | — | — | US | disclosed |
| EP-4551569-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-118159548-A | Antiviral compounds | 安力高医药股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| EP-4366831-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| US-20240109871-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-04-04 | — | — | US | disclosed |
| US-20240018126-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-01-18 | — | — | US | disclosed |
| US-20240018126-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-01-18 | — | — | US | disclosed |
| US-20240018126-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-01-18 | — | — | US | disclosed |
| WO-2024010794-A1 | ANTI-VIRAL COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-11851422-B2 | Anti-viral compounds | ALIGOS THERAPEUTICS, INC. | 2023-12-26 | — | — | US | disclosed |
| US-20230093249-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-03-23 | — | — | US | disclosed |
| WO-2023283256-A1 | ANTI-VIRAL COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243187-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | CYP1A2 3530/4885ARG1 1326/4885ARG2 1663/4885 |
| US-20230093249-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | CYP1A2 3530/4885ARG1 1326/4885ARG2 1663/4885 |
| US-11851422-B2 | Anti-viral compounds | EIF2AK2, ZC3HAV1, HAVCR2 | CYP1A2 3530/4885ARG1 1326/4885ARG2 1663/4885 |
| US-20240018126-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | CYP1A2 3530/4885ARG1 1326/4885ARG2 1663/4885 |
| US-20240109871-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | CYP1A2 3530/4885ARG1 1326/4885ARG2 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.